Sarepta Therapeutics (NASDAQ:SRPT) Shareholders Have Earned a 31% CAGR Over the Last Three Years
Sarepta Therapeutics (NASDAQ:SRPT) Shareholders Have Earned a 31% CAGR Over the Last Three Years
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But if you buy shares in a really great company, you can more than double your money. To wit, the Sarepta Therapeutics, Inc. (NASDAQ:SRPT) share price has flown 123% in the last three years. How nice for those who held the stock! It's also up 22% in about a month.
買入股票有風險,但如果你不用槓桿買,最壞的情況就是股價變爲零。但如果你買了一家非常好的公司的股票,你可以翻倍。按照這種想法,過去三年中Sarepta Therapeutics,Inc.(NASDAQ:SRPT)的股價飆升了123%。對於持有該股票的人來說,這是多麼美好!約一個月前,它上漲了22%。
Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.
現在值得更詳細地了解該公司的基本面,因爲這將幫助我們判斷長期股東回報是否與基礎業務的表現相匹配。
Given that Sarepta Therapeutics only made minimal earnings in the last twelve months, we'll focus on revenue to gauge its business development. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. It would be hard to believe in a more profitable future without growing revenues.
由於Sarepta Therapeutics在過去十二個月中僅獲得微薄的收入,因此我們將專注於營業收入以評估其業務發展。一般來說,我們會將這樣的股票和虧損的公司放在一起,僅僅因爲利潤的數量太低了。如果沒有不斷增長的營收,很難相信未來的利潤會更高。
Over the last three years Sarepta Therapeutics has grown its revenue at 28% annually. That's well above most pre-profit companies. Along the way, the share price gained 31% per year, a solid pop by our standards. This suggests the market has recognized the progress the business has made, at least to a significant degree. Nonetheless, we'd say Sarepta Therapeutics is still worth investigating - successful businesses can often keep growing for long periods.
在過去三年中,Sarepta Therapeutics的營業收入年均增長28%。這遠高於大多數未盈利公司。在此過程中,該股的價格每年增長31%,按我們的標準來看,這是一個不錯的漲勢。這表明市場已經認識到該企業已取得進展,至少在相當大的程度上是如此。儘管如此,我們認爲還是值得研究Sarepta Therapeutics-成功的企業往往可以保持長時間的增長。
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
你可以在下面的圖片中看到收入和營業收入隨時間的變化情況(單擊圖表可查看精確值)。
![big](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240712/0-1f692810712a10fe0a40fdf42844dd69-0-ddb7c96e6c650470d3de48bde7bf562d.png/big)
We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. So it makes a lot of sense to check out what analysts think Sarepta Therapeutics will earn in the future (free profit forecasts).
我們很高興看到內部人士在過去十二個月中一直在買入股票。即使如此,未來的盈利更加重要,這與當前股東是否賺錢有很大關係。因此,查看分析師對Sarepta Therapeutics未來盈利的預測(免費利潤預測)是非常有意義的。
A Different Perspective
不同的觀點
It's good to see that Sarepta Therapeutics has rewarded shareholders with a total shareholder return of 38% in the last twelve months. There's no doubt those recent returns are much better than the TSR loss of 0.6% per year over five years. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Sarepta Therapeutics is showing 2 warning signs in our investment analysis , and 1 of those can't be ignored...
令人高興的是,Sarepta Therapeutics在過去十二個月中以38%的股東回報率回報股東。毫無疑問,這些最近的回報比過去五年的年化TSR虧損率0.6%要好得多。我們通常更注重長期表現而不是短期表現,但最近的改善可能預示着業務內的(積極)拐點。儘管值得考慮市場條件對股價的不同影響,但還有其他更重要的因素。即使如此,請注意Sarepta Therapeutics在我們的投資分析中顯示出了2個警告信號,其中一個無法忽略...
Sarepta Therapeutics is not the only stock that insiders are buying. For those who like to find lesser know companies this free list of growing companies with recent insider purchasing, could be just the ticket.
Sarepta Therapeutics並不是唯一一家內部人士在過去十二個月中購買股票的公司。對於那些喜歡發掘不知名公司的人來說,這個免費列表列出了最近有內部人士買入的成長型公司。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關注內容?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋? 對內容感到擔憂? 請直接與我們聯繫。 或者,發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。